Pharma TeleWeb e-Detailing
This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.
Pharma Marketing News Vol. 10, No. 11: 21 June 2011
Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.
New Big Pharma Economies of Scale
How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?
Pharma Companies Behaving Badly
Every year without fail there are revelations about pharmaceutical companies behaving badly -- companies that have been charged with crimes such as making kickbacks to physicians, engaging in Medicare and Medicaid fraud, promoting products off label to physicians or companies that are called to testify before Congress about sub par manufacturing practices. 2010 seems to be unique in the number of companies behaving badly.
Deconstructing Pitts’ Guiding Principles for Pharma Social Media
Peter Pitts, author of DrugWonks Blog, has put together 11
The Changing Pharma eDetailing Landscape
A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.
How to Score With Women (as a Marketer) via Social Media
A conversation with Casey Quinlan, 'Mighty Mouth' at Mighty Casey Media LLC, Zoe Dunn, Principal, Hale Advisors, Richard Meyer, Principal Consultant, Online Strategic Solutions, Jerry Hall, Digital Media Executive, Advisor to Pearescope, about engaging and marketing to women online, especially via social media, which some new media marketers claim is 'all about women.'
Pharma Marketing News Vol. 10, No. 12: 20 July 2011
Welcome to Volume 10, Issue #12 (20 JULY 2011) of Pharma Marketing News.
Orphan Drugs Now “Where the Money Is,” Says Willie Sutton’s Ghost
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
The Digital Health Coalition: Solving Real Problems — Mission Possible?
A conversation with Mark Bard, founder of the Digital Health Coalition, regarding the mission of the Coalition and what companies and individuals are involved.
